Gilbert Ruth E, Harden Melissa
Centre for Evidence-based Child Health, MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health, London, UK.
Curr Opin Infect Dis. 2008 Jun;21(3):235-45. doi: 10.1097/QCO.0b013e3282ffd6e0.
Clinicians need information on the relative effectiveness of different types of impregnated central venous catheter for serious infection and their relative costs and adverse effects in order to decide which type, if any, to use.
We systematically reviewed 37 randomized controlled trials involving 11 586 patients. Only seven studies were classified as good on all measures of study quality. Compared with standard catheters, significant and substantial reductions in catheter-related blood stream infection were found for heparin-coated and antibiotic-impregnated central venous catheters. We found no statistically significant benefits of antiseptic central venous catheters, coated with chlorhexidine and silver sulphadiazine, or sliver-impregnated central venous catheters, compared with standard catheters. The few 'head-to-head' comparisons confirmed the benefits of antibiotic impregnation compared with chlorhexidine and silver sulphadiazine or silver impregnation, but no significant difference was found for heparin-coated compared with silver-impregnated central venous catheters. No studies reported serious adverse events, but there is some evidence of antibiotic resistance from in-vitro studies. No impregnated central venous catheter exists for neonates weighing less than 3 kg, and few studies have been undertaken in larger children.
The most promising options for reducing catheter-related blood stream infection are heparin-coated or antibiotic-impregnated central venous catheters. Large, high-quality randomized controlled trials are needed to evaluate which of these methods is most effective for reducing clinically important consequences of catheter-associated infection.
临床医生需要了解不同类型的中心静脉导管在预防严重感染方面的相对有效性、相对成本及不良反应,以便决定使用何种类型(如有)。
我们系统回顾了37项随机对照试验,涉及11586例患者。只有7项研究在所有研究质量指标上被评为良好。与标准导管相比,肝素涂层和抗生素涂层的中心静脉导管在降低导管相关血流感染方面有显著且实质性的减少。我们发现,与标准导管相比,洗必泰银磺胺嘧啶涂层的抗菌中心静脉导管或银涂层中心静脉导管没有统计学上显著的益处。少数“头对头”比较证实了抗生素涂层与洗必泰银磺胺嘧啶涂层或银涂层相比的益处,但肝素涂层与银涂层中心静脉导管相比没有显著差异。没有研究报告严重不良事件,但体外研究有一些抗生素耐药性的证据。对于体重小于3kg的新生儿没有可用的涂层中心静脉导管,且针对较大儿童的研究较少。
降低导管相关血流感染最有前景的选择是肝素涂层或抗生素涂层的中心静脉导管。需要开展大型、高质量的随机对照试验来评估哪种方法在降低导管相关感染的临床重要后果方面最有效。